Summary by Futu AI
Tonix Pharmaceuticals Holding Corp. reported an amendment to its Schedule 13G/A filing, indicating that Tang Capital Partners, LP, Tang Capital Management, LLC, and Kevin Tang collectively own 0 shares of the company's common stock, representing 0.0% of the class. The amendment, filed with the Securities and Exchange Commission, was dated December 31, 2023, and the information was submitted on February 14, 2024. The filing signifies that the reporting entities have ceased to be the beneficial owners of more than five percent of Tonix Pharmaceuticals' common stock. The entities involved are organized under the laws of Delaware, and Kevin Tang is a United States citizen. The filing includes a certification by Kevin Tang, stating that the shares were not acquired with the purpose of changing or influencing the control of the issuer, nor were they held in connection with any transaction having that purpose or effect.